KDR and pancreatic neoplasm: The aggregate data for DC101 treatment indicate that specifically targeting tumor vasculature (via VEGFR-2) in these primary pancreatic tumors has a minor effect in one tumor line, but that in general, the tumors in both groups behaved like Veh-ctrl tumors and continued expanding outwards from a central necrotic core.